Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13934
Country/Region: Ethiopia
Year: 2016
Main Partner: Addis Ababa Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $5,372,237 Additional Pipeline Funding: $200,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $676,136
Care: TB/HIV (HVTB) $143,859
Care: Pediatric Care and Support (PDCS) $115,231
Laboratory Infrastructure (HLAB) $46,320
Strategic Information (HVSI) $83,362
Health Systems Strengthening (OHSS) $36,302
Biomedical Prevention: Blood Safety (HMBL) $17,098
Testing: HIV Testing and Counseling (HVCT) $74,128
Sexual Prevention: Other Sexual Prevention (HVOP) $64,053
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $460,348
Treatment: Adult Treatment (HTXS) $3,228,342
Treatment: Pediatric Treatment (PDTX) $427,058
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 522
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 390
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 586
GEND_GBV Number of people receiving post-GBV care 2017 978
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 4,677
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 4,868
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 150,341
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 77,242
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 237,128
HTS_TST Service Delivery Point (Facility): Inpatient 2017 18,973
HTS_TST Service Delivery Point (Facility): Other PITC 2017 12,636
HTS_TST Service Delivery Point (Facility): Outpatient 2017 72,728
HTS_TST Service Delivery Point (Facility): Pediatric 2017 211
HTS_TST Service Delivery Point (Facility): PMTCT 2017 79,031
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 14,228
HTS_TST Service Delivery Point (Facility): VCT 2017 39,531
HTS_TST Sum of Aggregated Age/Sex <15 2017 9,545
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 227,583
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 237,128
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 436
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 482
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 6,634
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3,813
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 2,400
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 2,400
KP_PREV Total estimated number of key population in the catchment area 2017 3,400
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 3,400
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 12
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 12
LAB_PT CD4: Number of laboratories that perform this testing 2017 19
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 3
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 85
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 85
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 85
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 12
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 12
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 85
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 4
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 5
PMTCT_ART Already on ART at beginning of current pregnancy 2017 675
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,560
PMTCT_ART New on ART 2017 248
PMTCT_ART New on ART 2017 1,080
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 31,646
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 73,521
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 543
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,249
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 134
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 566
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 2
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 33
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 10
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 56
PMTCT_EID Sum of Infant Age disaggregates 2017 677
PMTCT_EID Sum of Infant Age disaggregates 2017 2,815
PMTCT_STAT By: Known positives at entry 2017 676
PMTCT_STAT By: Known positives at entry 2017 1,714
PMTCT_STAT By: Number of new positives identified 2017 280
PMTCT_STAT By: Number of new positives identified 2017 1,098
PMTCT_STAT Number of new ANC and L&D clients 2017 33,503
PMTCT_STAT Number of new ANC and L&D clients 2017 75,843
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 31,646
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 73,521
PMTCT_STAT Sum of Positives Status disaggregates 2017 956
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,812
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 16,671
PP_PREV Total number of people in the target population 2017 19,703
PrEP_NEW Number of individuals who have received antiretroviral preexposure 2017 191
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 133
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 845
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 173
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,075
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 2,226
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 2,226
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 5,280
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 1,583
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 1,586
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,111
TB_SCREENDX Screen Result: Screened Positive for TB 2017 7,534
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 43,335
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 24,921
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 2,998
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 4,045
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 75,326
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 472
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 17
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,007
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 104
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 633
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 22
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,792
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 132
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 7,924
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 275
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 7,939
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 281
TX_CURR Aggregated Age/Sex: <15 Female 2017 61
TX_CURR Aggregated Age/Sex: <15 Female 2017 2,961
TX_CURR Aggregated Age/Sex: <15 Male 2017 74
TX_CURR Aggregated Age/Sex: <15 Male 2017 4,178
TX_CURR Aggregated Age/Sex: 15+ Female 2017 6,083
TX_CURR Aggregated Age/Sex: 15+ Female 2017 44,988
TX_CURR Aggregated Age/Sex: 15+ Male 2017 6,006
TX_CURR Aggregated Age/Sex: 15+ Male 2017 25,821
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 12,224
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 77,948
TX_CURR Sum of Aggregated Age/Sex <15 2017 135
TX_CURR Sum of Aggregated Age/Sex <15 2017 7,139
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 12,089
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 70,809
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 12,224
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 77,948
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 26
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 597
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 42
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 661
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 1,468
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 6,984
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,070
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,998
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 2,606
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 12,242
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 2,606
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 12,240
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 7,334
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 50,196
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 40,370
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 5,501
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 26
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,556
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 32
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,150
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 2,738
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 23,266
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 2,705
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 13,332
TX_PVLS Numerator: Indication: Routine 2017 4,951
TX_PVLS Numerator: Indication: Routine 2017 32,294
TX_PVLS Numerator: Indication: Targeted 2017 550
TX_PVLS Numerator: Indication: Targeted 2017 8,076
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 39
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,944
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 45
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,676
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 3,651
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 28,610
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,600
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 16,666
TX_PVLS_den Denominator: Indication: Routine 2017 6,601
TX_PVLS_den Denominator: Indication: Routine 2017 40,154
TX_PVLS_den Denominator: Indication: Targeted 2017 733
TX_PVLS_den Denominator: Indication: Targeted 2017 10,968
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 42
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 268
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 50
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 318
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 467
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,048
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 257
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,663
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 816
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 5,297
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 950
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 6,139
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 49
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 311
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 58
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 369
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 541
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,529
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 293
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,930
Cross Cutting Budget Categories and Known Amounts Total: $1,051,191
Human Resources for Health $81,872
Food and Nutrition: Policy, Tools, and Service Delivery $87,898
Renovation $689,500
Motor Vehicles: Purchased $120,000
Key Populations: Sex Workers $41,621
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $30,300
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Implementation
Capacity building
Monitoring and Evaluation